Cochrane · systematic review · CD001405
Oestrogen therapy for urinary incontinence in post‐menopausal women
Cody, JD, Jacobs, ML, Richardson, K, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
IncontinenceAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 8.3%Low 4 · 33.3%Moderate 6 · 50%High 1 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oestrogen compared to placebo or no treatment for urinary incontinence in post‐menopausal women
Population: patients with urinary incontinence in post‐menopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incontinence not improved (generic inverse variance) (women's observations) ‐ Systemic administration (any incontinence) Oestrogen vs placebo or no treatment | RR 1.32 [1.17, 1.48] | 6 studies · 6151 participants | Low |
Incontinence not improved (generic inverse variance) (women's observations) ‐ Local administration (any incontinence) Oestrogen vs placebo or no treatment | RR 0.74 [0.64, 0.86] | 4 studies · 213 participants | Very low Downgraded: risk of bias, inconsistency |
Incontinent episodes over 24 hours ‐ Systemic administration Oestrogen vs placebo or no treatment | no estimate extracted | 2 studies · 82 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Number of women with urgency ‐ Systemic administration Oestrogen vs placebo or no treatment | RR 1.05 [0.83, 1.33] | 2 studies · 89 participants | Moderate Downgraded: inconsistency |
Number of women with urgency ‐ Local administration Oestrogen vs placebo or no treatment | RR 0.38 [0.15, 0.99] | 2 studies · 90 participants | Moderate Downgraded: inconsistency |
Number with adverse effects ‐ Systemic administration Oestrogen vs placebo or no treatment | RR 13 [1.87, 90.21] | 1 study · 40 participants | Low Downgraded: imprecision |
Number with adverse effects ‐ Local administration Oestrogen vs placebo or no treatment | RR 1.33 [0.32, 5.61] | 2 studies · 144 participants | Moderate Downgraded: imprecision |
Oestrogen versus other treatments for urinary incontinence in post‐menopausal women
Population: patients with urinary incontinence in post‐menopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number with incontinence not improved (women's observations) ‐ Oestrogen vs PPA Oestrogen vs other treatments | RR 0.83 [0.63, 1.09] | 2 studies · 57 participants | Moderate |
Adverse effects ‐ oestrogen vs PPA Oestrogen vs other treatments | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Oestrogen + other treatments versus placebo for urinary incontinence in post‐menopausal women
Population: patients with urinary incontinence in post‐menopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incontinent episodes over 24 hours ‐ oestrogen + progesterone vs placebo Oestrogen + other treatments vs placebo | no estimate extracted | 1 study · 83 participants | Moderate Downgraded: imprecision |
Incontinence not improved (generic inverse variance) (women's observation) ‐ oestrogen + other treatments versus placebo Oestrogen + other treatments vs placebo | RR 1.11 [1.04, 1.18] | 3 studies · 10635 participants | Moderate |
Number with incontinence not improved (women's observations) ‐ oestrogen + progesterone vs placebo (Copy) Oestrogen + other treatments vs placebo | RR 1.08 [1.01, 1.16] | 2 studies · 1514 participants | High |